AOD-9604 vs Pramlintide
A neutral, side-by-side comparison of two metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
AOD-9604
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH), specifically amino acids 176–191. It was developed to replicate the fat-metabolizing activity of hGH without the growth-promoting, insulin-desensitizing, or mitogenic effects of full-length hGH. Research has focused on its ability to stimulate lipolysis and inhibit lipogenesis through a non-GHR-dependent mechanism.
Full profilePramlintide
Synthetic amylin analogue (Symlin) approved as an adjunct to insulin for both type 1 and type 2 diabetes. Amylin is normally co-secreted with insulin from pancreatic beta cells, but is deficient in T1D (beta cell destruction) and reduced in T2D. Pramlintide replaces this missing signal to reduce post-meal glucose spikes and food intake.
Full profile| AOD-9604 | Pramlintide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Also known as | Anti-Obesity Drug 9604, hGH Fragment 176-191, Tyr-hGH Frag 176-191 | Symlin, AC137, synthetic amylin |
| Evidence | Investigational (in trials) | FDA-approved |
| Dosing range | 250mcg–1000mcg mcg, Once daily, on an empty stomach | 15mcg–120mcg mcg, Before major meals (3x daily) |
| Administration | Subcutaneous injection, Oral (significantly reduced bioavailability) | Subcutaneous injection |
| Key side effects | Injection site redness or irritation, Mild flushing (transient), Headache (rare), Considered low side-effect profile compared to full hGH | Nausea (most common, often transient in first 4 weeks), Hypoglycemia risk (when combined with insulin — insulin dose reduction required), Vomiting, Decreased appetite |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: AOD-9604 is investigational (in trials), while Pramlintide is fda-approved.
- Administration: AOD-9604 — Subcutaneous injection, Oral (significantly reduced bioavailability); Pramlintide — Subcutaneous injection.
- Frequency: AOD-9604 is typically Once daily, on an empty stomach; Pramlintide is Before major meals (3x daily).
- Research depth: this profile cites 3 sources for AOD-9604 vs 2 for Pramlintide.
How each works
AOD-9604
Animal studies consistently demonstrate that AOD-9604 reduces body fat in obese rodents without affecting blood glucose or IGF-1 levels — a significant distinction from hGH. It appears to act directly on fat cells via beta-adrenergic pathways. Phase 2 human clinical trials for obesity were conducted but did not meet primary endpoints for the oral formulation; injectable forms were not advanced to Phase 3. AOD-9604 received GRAS (Generally Recognized As Safe) status in the US for food use, though this does not confer therapeutic approval.
Pramlintide
Pramlintide reduces post-prandial glucose by three complementary mechanisms: slowing gastric emptying, suppressing post-meal glucagon secretion from alpha cells, and signaling meal-related satiety via brainstem amylin receptors. Phase 3 trials in both T1D and T2D demonstrated HbA1c reductions of 0.3–0.5% when added to insulin, with additional weight loss of 1–3kg — a welcome effect contrasting with insulin's typical weight gain.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.